TransMedics Group's ROE % for the quarter that ended in Mar. 2026 was 6.05%. TransMedics Group's PB Ratio for the quarter that ended in Mar. 2026 was 6.95.
TransMedics Group's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was 0.87%.
TransMedics Group ROE % Adjusted to Book Value Related Terms
TransMedics Group ROE % Adjusted to Book Value Historical Data
* Premium members only.
The historical data trend for TransMedics Group's ROE % Adjusted to Book Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TransMedics Group ROE % Adjusted to Book Value Chart
TMDX vs AXGN, BFLY, ESTA: ROE % Adjusted to Book Value Comparison
For the Medical Devices subindustry, TransMedics Group's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TransMedics Group ROE % Adjusted to Book Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TransMedics Group's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where TransMedics Group's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 0.87% mean?
TransMedics Group (TMDX) has a ROE % Adjusted to Book Value of 0.87% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TransMedics Group and its competitors.
Is TransMedics Group's ROE % Adjusted to Book Value too high?
TransMedics Group's current ROE % Adjusted to Book Value is 0.87%. Overall, TransMedics Group has a GF Score™ of 69/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does TransMedics Group's ROE % Adjusted to Book Value compare to AXGN and BFLY?
TransMedics Group's ROE % Adjusted to Book Value of 0.87% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Medical Devices & Instruments company?
A good ROE % Adjusted to Book Value depends on the Medical Devices & Instruments industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on TransMedics Group and its competitors. TransMedics Group's current ROE % Adjusted to Book Value is 0.87%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TransMedics Group stock overvalued right now?
Based on GuruFocus' analysis, TransMedics Group (TMDX) is currently considered Possible Value Trap. The stock's GF Value™ is $166.36, compared to a current price of $67.60 — trading 59.4% below its estimated fair value. The current ROE % Adjusted to Book Value is 0.87%. TransMedics Group's overall GF Score™ is 69/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For TransMedics Group (TMDX), the current ROE % Adjusted to Book Value is 0.87% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is TransMedics Group (TMDX) Overvalued in 2026?
Based on GuruFocus' analysis, TransMedics Group stock appears to be undervalued.
The current stock price of $67.60 is trading 59.4% below its estimated GF Value™ of $166.36.
GuruFocus considers TransMedics Group to be Possible Value Trap.
Key valuation signals for TMDX:
ROE % Adjusted to Book Value: 0.87%
GF Value™: $166.36 vs. price of $67.60 (59.4% below fair value)
No single metric tells the full story. See the TMDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
69GF Score
Get the complete analysis for TMDX
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TMDX has been successfully added to your 
